Human papillomavirus vaccination in survivors of childhood cancer

Cancer

Volumn 115, Issue 24, 2009, Pages 5627-5636

  Klosky, James L ^a   Gamble, Heather L ^a,b   Spunt, Sheri L ^a   Randolph, Mary E ^a   Green, Daniel M ^a   Hudson, Melissa M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b University of Memphis   (United States)

Author keywords

Cervical cancer; Complications; Human papillomavirus; Pediatric cancer; Survivorship; Vaccination

Indexed keywords

WART VIRUS VACCINE;

BRONCHOSPASM; CHILDHOOD CANCER; DEATH; DRUG EFFICACY; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTENSION; IMMUNE DEFICIENCY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VAGINA BLEEDING; WART VIRUS;

BEHAVIOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSION; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PAPILLOMAVIRUS VACCINES; PELVIS; RADIOTHERAPY; RISK FACTORS; SURVIVORS;

EID: 73149110612     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24669     Document Type: Review

References (80)

1. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 2007;7:304.
2. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.
3. Mariam A. Cervical cancer vaccines available in 2007. Drug Discov Today. 2005;10:949-950.
4. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
5. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-1171.
6. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
7. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2007. MMWR Surveill Summ. 2008;57:1-131.
8. Wulf D. In Their Own Right: Addressing the Sexual and Reproductive Health Needs of American Men. New York, NY: Alan Guttmacher Institute; 2002.
9. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
10. American Cancer Society. Cancer Facts & Figures, 2008. Atlanta, GA: American Cancer Society; 2008.
11. National Cancer Institute. National Cancer Institute Fact Sheet. 5.16th ed. The Pap Test: Questions and Answers. Bethesda, MD: National Cancer Institute; 2007.
12. Burchell AN, Winer RL, de Sanjose S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(suppl 3):S52-S61.
13. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol. 2007;107(2 suppl 1):S27-S30.
14. Paavonen J, Lehtinen M. Introducing human papillomavirus vaccines - questions remain. Ann Med. 2008;40:162-166.
15. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006.
16. Watson M, Saraiya M, Ahmed F, et al. Using populationbased cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113(10 suppl):2841-2854.
17. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367: 1247-1255.
18. Koutsky LA, Harper DM. Current findings from prophylactic HPV vaccine trials. Vaccine. 2006;24(suppl 3):S114-S121.
19. Centers for Disease Control. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56(RR-2):1-26.
20. United States Food and Drug Administration. HPV (human papillomavirus) 2006. Available to: http://www.fda.gov/womens/getthefacts/hpv.html. Accessed on June 18, 2008.
21. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
22. Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis. 2007;11(suppl 2):S17-S25.
23. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
24. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
25. Twombly R. U.S. girls to receive HPV vaccine but picture unclear on potential worldwide use, acceptance. J Natl Cancer Inst. 2006;98:1030-1032.
26. Hoffman J. Vaccinating boys for girls' sake? New York Times. February 24, 2008:ST1.
27. Merck Pharmaceutical Company. Gardasil, Merck's cervical cancer vaccine, demonstrated efficacy in preventing HPV-related disease in males in phase III study. Research & Development News, 2008.
28. Malouf MA, Hopkins PM, Singleton L, Chhajed PN, Plit ML, Glanville AR. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant. 2004;23:894-897.
29. Rose B, Wilkins D, Li W, et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. Transplantation. 2006;82:570-573.
30. Courtney AE, Leonard N, O'Neill CJ, McNamee PT, Maxwell AP. The uptake of cervical cancer screening by renal transplant recipients. Nephrol Dial Transplant. 2009;24:647-652.
31. Vacher-Coponat H, Dussol B, Berland Y. Neoplastic disorders and organ transplantation [in French]. Rev Med Interne. 1999;20:992-1003.
32. Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation. 1996;62:476-479.
33. Seshadri L, George SS, Vasudevan B, Krishna S. Cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant recipients. Indian J Cancer. 2001;38:92-95.
34. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci. 2004;328:57-63.
35. Fruchter RG, Maiman M, Arrastia CD, Matthews R, Gates EJ, Holcomb K. Is HIV infection a risk factor for advanced cervical cancer? J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:241-245.
36. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91:226-236.
37. Di Stefano L, Coppola G, Moro S, Colageo E, Cellini A, Coletti G. Cervical-vaginal disease in HIV immunosuppressed patients: management and present screening programme. Eur J Gynaecol Oncol. 2006;27:267-270.
38. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, et al. Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol. 2006;103:1017-1022.
39. Sirivongrangson P, Bollen LJ, Chaovavanich A, et al. Screening HIV-infected women for cervical cancer in Thailand: findings from a demonstration project. Sex Transm Dis. 2007;34:104-107.
40. Bunin N, DiDomenico C, Guzikowski V. Hematopoietic stem cell transplantation. In: Schwartz CL, Hobbie WL, Constine LS, Ruccione KS, eds. Survivors of Childhood and Adolescent Cancer. Berlin, Germany: Springer; 2005:271-282.
41. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18:348-357.
42. Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant. 2001;28:393-397.
43. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19:464-471.
44. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin's disease on the immune system. Semin Oncol. 1990;17:673-682.
45. Slivnick DJ, Nawrocki JF, Fisher RI. Immunology and cellular biology of Hodgkin's disease. Hematol Oncol Clin North Am. 1989;3:205-220.
46. Serraino D, Franceschi S, Talamini R, et al. Socio-economic indicators, infectious diseases and Hodgkin's disease. Int J Cancer. 1991;47:352-357.
47. Gross G, Ellinger K, Roussaki A, Fuchs PG, Peter HH, Pfister H. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol. 1988;91:43-48.
48. Hennig EM, Nesland JM, Di Lonardo A, Venuti A. Multiple primary cancers and HPV infection: are they related? J Exp Clin Cancer Res. 1999;18:53-54.
49. KatzRL, Veanattukalathil S, WeissKM. Human papillomavirus infection and neoplasia of the cervix and anogenital region in women with Hodgkin's disease. Acta Cytol. 1987;31:845-854.
50. Quayle AJ. The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J Reprod Immunol. 2002;57:61-79.
51. Fujimura M, Ostrow RS, Okagaki T. Implication of human papillomavirus in postirradiation dysplasia. Cancer. 1991;68:2181-2185.
52. Barzon L, Pizzighella S, Corti L, Mengoli C, Palu G. Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus. J Med Virol. 2002;67:401-405.
53. Seidman JD, Kumar D, Cosin JA, Winter WE III, Cargill C, Boice CR. Carcinomas of the female genital tract occurring after pelvic irradiation: a report of 15 cases. Int J Gynecol Pathol. 2006;25:293-297.
54. Yeazel MW, Oeffinger KC, Gurney JG, et al. The cancer screening practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2004;100:631-640.
55. Castellino SM, Casillas J, Hudson MM, et al. Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study. J Clin Oncol. 2005;23:6499-6507.
56. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004;2:61-70.
57. Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young adult survivors of childhood cancer. Psychooncology. 2004;13:689-699.
58. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000;15:603-630.
59. Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol. 1991;9:1348-1356.
60. Flory K, Molina BSG, Pelham WE Jr, Gnagy E, Smith B. Childhood ADHD predicts risky sexual behavior in young adulthood. J Clin Child Adolesc Psychol. 2006;35:571-577.
61. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45:192-202.
62. Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer. 2008;113 (10 suppl):2910-2918.
63. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24(suppl 3):S3/11-S3/25.
64. Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2390-2395.
65. Kahn JA, Rosenthal SL, Jin Y, et al. Vaccine-type HPV infection and post-licensure attitudes about HPV vaccination in young women. J Adolesc Health. 2008;42(2 suppl 1):28-29.
66. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol. 2008;111:1103-1110.
67. Centers for Disease Control. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:1100-1103.
68. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003;30:774-778.
69. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45:107-114.
70. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188-194.
71. Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis. 2007;34:468-471.
72. Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. Pediatrics. 1999;104(1 pt 1):35-42.
73. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 2000;9:47-50.
74. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians" intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005;37:502-510.
75. Kahn JA, Rosenthal SL, Tissot AM, Bernstein DI, Wetzel C, Zimet GD. Factors influencing pediatricians" intention to recommend human papillomavirus vaccines. Ambul Pediatr. 2007;7:367-373.
76. Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics. 2006;118:2280-2289.
77. Marlow LA, Waller J, Wardle J. Parental attitudes to prepubertal HPV vaccination. Vaccine. 2007;25:1945-1952.
78. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486-1493.
79. Mulhern RK, Tyc VL, Phipps S, et al. Health-related behaviors of survivors of childhood cancer. Med Pediatr Oncol. 1995;25:159-165.
80. Weinberg A, Song LY, Handelsman E, et al. Safety and immunogenicity of a quadrivalent vaccine to prevent human papilloma virus infection in HIV-infected children: IMPAACT P1047. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, Massachusetts.